Hemispherx Biopharma Inc.’s vow to appeal a second FDA “complete response” letter for Ampligen (rintatolimod) suggests the investigational chronic fatigue drug will remain in developmental limbo for the foreseeable future.
In a Feb. 4 press release announcing receipt of the action letter, Hemispherx showed no willingness to accede to FDA’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?